Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Jul 31, 2024
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2024-07-30$1.06/sh−2,883$3,056→ 326,628 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.